Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glycoconjugate vaccines: future combinations

P R Paradiso1, A A Lindberg

  • 1Wyeth-Lederle Vaccines & Pediatrics, West Henrietta NY, USA.

Developments in Biological Standardization
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maternal immunization: the influence of liability issues on vaccine development.

Vaccine·2001
Same author

Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children.

Lancet (London, England)·2001
Same author

Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants.

The Pediatric infectious disease journal·2001
Same author

Polyosides (encapsulated bacteria).

Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie·2000
Same author

Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity.

Vaccine·2000
Same author

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2000
Same journal

International challenges and public policy issues.

Developments in biological standardization·2000
Same journal

Regulation of biologicals in China.

Developments in biological standardization·2000
Same journal

ICH activities on biotech topics.

Developments in biological standardization·2000
Same journal

Regulation of biologicals in the European Union.

Developments in biological standardization·2000
Same journal

Standardisation and licensing of combination vaccines based on DTP.

Developments in biological standardization·2000
Same journal

Control of foot-and-mouth disease by vaccination.

Developments in biological standardization·2000
See all related articles

Developing effective glycoconjugate vaccines against encapsulated bacteria requires understanding antibody levels for protection. Determining precise correlates of immunity is crucial for new vaccine formulations and combinations.

Area of Science:

  • Immunology
  • Vaccinology
  • Microbiology

Background:

  • Knowledge of immune responses to encapsulated bacteria aids glycoconjugate vaccine development.
  • Anti-saccharide antibody responses are understood to be protective against pathogens like Haemophilus influenzae type b, Streptococcus pneumoniae, Neisseria meningitidis, and Streptococcus agalactiae.

Purpose of the Study:

  • To address the critical question of the required magnitude of anti-saccharide antibody response for protection.
  • To discuss the challenges in establishing precise antibody correlates of immunity for vaccine efficacy.
  • To explore the implications for developing multivalent vaccines and vaccine combinations.

Main Methods:

  • Review of existing knowledge on immune responses to encapsulated bacterial pathogens.

Related Experiment Videos

  • Analysis of data from field trials of Haemophilus influenzae type b vaccines.
  • Discussion of challenges in efficacy studies for new serotypes and low-incidence diseases.
  • Consideration of immunogenicity studies for combined vaccine products.

    • Main Results:

    • Precise antibody correlates of immunity are not yet established, even for licensed vaccines like Haemophilus influenzae type b.
    • Field trials are necessary to determine efficacy and correlates for multivalent pneumococcal vaccines.
    • Efficacy studies for individual serotypes in multivalent formulations are often infeasible.
    • Comparative immunogenicity studies are essential for ensuring efficacy of combined vaccine antigens due to potential interference.

    Conclusions:

    • Establishing reliable antibody correlates of immunity is vital for the development and licensure of new and combination glycoconjugate vaccines.
    • The complexity of multivalent and combined vaccines necessitates robust methods for measuring component stability and immunogenicity.
    • Further research is needed to define protective antibody thresholds for various encapsulated bacterial pathogens.